Australia markets open in 16 minutes

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.2300+0.0700 (+6.03%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.1600
Open1.1800
Bid1.1800 x 800
Ask1.2400 x 1100
Day's range1.1650 - 1.2300
52-week range0.7310 - 4.3000
Volume161,465
Avg. volume158,544
Market cap111.441M
Beta (5Y monthly)0.43
PE ratio (TTM)N/A
EPS (TTM)-0.9010
Earnings date27 Mar 2023 - 31 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.92
  • GlobeNewswire

    Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement

    BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan

  • GlobeNewswire

    Genetron Health Announces Receipt of Notification from Nasdaq

    BEIJING, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated October 28, 2022, indicating that fo

  • GlobeNewswire

    Genetron Health Reports Unaudited Second Quarter 2022 Financial Results

    BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022. Recent Business Highlights Received College of American Pathologists (CAP) Accreditation for its laboratory